参考资料（上下滑动查看全部）：

[1]Liu S, Yin Z, Yu X, Zhao Y, Pan J, Song Y. CD19-specific CAR-T cell therapy for relapsed/refractory non-B-cell acute leukaemia with CD19 antigen expression. Eur J Cancer. 2021 Aug;153:1-4. doi: 10.1016/j.ejca.2021.04.042. Epub 2021 Jun 11. PMID: 34126332.

[2]CD22-TAGETED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR ADULTS WITH REFRACTORY OR RELAPSED B ACUTE LYMPHOBLASTIC LEUKEMIA. 2021 EHA. Abstract EP344.

[3]Liu S, Deng B, Yin Z, Lin Y, An L, Liu D, Pan J, Yu X, Chen B, Wu T, Chang AH, Tong C. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. Am J Hematol. 2021 Jun 1;96(6):671-679. doi: 10.1002/ajh.26160. Epub 2021 Mar 29. PMID: 33725422.

[4]An L, Lin Y, Deng B, Yin Z, Zhao D, Ling Z, Wu T, Zhao Y, Chang AH, Tong C, Liu S. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy. BMC Cancer. 2022 Apr 12;22(1):393. doi: 10.1186/s12885-022-09489-1. PMID: 35410148; PMCID: PMC9004014.

[5]CD58 Could Be as a Leukemic Marker in Relapsed/Refractory B-ALL Patients after Multiline Therapies. ASH 2022 P434

[6]Combination of InotuzumabOzogamicin and Olverembatinib as Salvage Therapy for Elderly Patients with Relapsed and Refractory Ph+ B-ALL. EBMT2023 P271

[7]THE TREATMENT RESPONSE OF A TWO-DOSE REGIMEN OF DOSE-ADJUSTED INOTUZUMAB IN RELAPSED/REFRACTORY B-ALL. EHA 2023 P387

[8]OBSERVATION OF THERAPEUTIC EFFECT OF BLINATUMOMAB SALVAGE TREATMENT ON B-ALL WITH INVALID OR RECURRENT CART. EHA 2023 PB1738

[9]Clinical Implications of Germline Predisposition Gene Variants in Patients with Refractory or Relapsed B Acute Lymphoblastic Leukemia. ASH 2023 P1612